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e.2012.10Abstract New factors such as the G protein coupled receptor (GPCR) surrounding’s chemical
environment, cell membrane constituents, the existent gap junction, endogenous receptor afﬁnity
status and animal species have been shown to inﬂuence the GPCR physiology and variations of
those factors can modify the functions of the GPCRs, thus highlighting the possibility to exploit
these properties in different pharmacological ﬁelds which may lead to obtaining new therapeutic
methods and applications. Furthermore, it might help in developing new research methods.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2. Chemical environment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2.1. Manganese inﬂuence serotonergic receptor 1 properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23. Cholesterol and membrane inﬂuence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
4. Gap junction’s electrical synapses role in neuropathologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
5. High and low-afﬁnity receptor states in vivo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
6. Animal species inﬂuence on ligand–receptor interaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3ress: Department of Pharma-
ity, No. 24 Tong Jia Xiang,




xandria University Faculty of
g by Elsevier
y Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.
.002
2 A. Ghanemi et al.7. Conclusions and perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41. Introduction
In addition of the classical factors linked to pharmacodynam-
ics, different studies have led to the discovery of new factors
that may inﬂuence the activity of molecules acting on GPCR
systems. Such factors will be added to those already known
including those related to structure/activity relationship (some
aspects have been described by Spedding1), physicochemical
properties of the agents, patient population and pharmacolog-
ical interactions. Within the coming examples we focus on one
element: ‘‘As a factor has been shown to inﬂuence at least one
of the elements of the GPCRs system, we suppose that the
same factor or another factor that has the same properties
may inﬂuence one or more GPCR-related systems, and this be-
cause of the analogies that exist between GPCRs. On the oth-
ers hand the factors have been illustrated by selected examples
to clarify the concept and introduce the implications.
2. Chemical environment
A recent research pointed out that receptor density, ionic envi-
ronment and the cell type may inﬂuence the pharmacological
properties of aripiprazole (an antipsychotic dopamine D2
receptor partial agonist used in the treatment of psychosis)
and other partial agonists of the D2.2 Furthermore, previous
researches have described that sodium ions decrease the G pro-
tein coupling of dopamine receptors3,4 and that the surround-
ing environment (including sodium ions and depending on the
brain area) in addition to receptor density modify both prop-
erties of functional selective ligands and the afﬁnity of ago-
nists.2 Indeed, the interaction of the conserved aspartate
residue within the transmembrane core of several GPCRs with
sodium ions may change the receptor conformation, thus inﬂu-
encing the related pathways activation.3,5 Furthermore the po-
tential of intra- or extracellular sodium concentrations to
modify GPCRs binding and signaling has also been pointed
out .5
Such data make researches essential to be carried out to
clarify the role sodium ions may play in the ability of GPCRs
to signal in vivo2 especially that such differences in ionic envi-
ronment may exist between brain structures supposing that the
same ligand may act on the same kind of receptors in different
brain areas and produce non similar effects because the impact
of sodium ions, or probably other ions, on the ability of GPCR
to signal.
2.1. Manganese inﬂuence serotonergic receptor 1 properties
Another toxicological aspect about GPCR–manganese
(Mn2+) interactions illustrates the inﬂuences that ions can
have on GPCR properties. Mn2+ accumulates in the CNS6–8
within regions such as basal ganglia, cortical and hippocampal
regions of the brain9–11 and therefore may explain the different
symptoms related to the overexposure to manganese. Indeedsymptoms of Mn2+ poisoning (named manganism) have sim-
ilarities with Parkinson’s disease (PD) so the dopaminerigic
pathway was pointed at to explain its toxicodynamics, whereas
the serotonergic system has been shown to be probably impli-
cated.12 Two papers13,14 pointed out that manganese consti-
tutes an inducer of agonist high-afﬁnity binding to 5-HT1A
receptors. The manganism-associated symptoms include
impulsiveness, psychosis with euphoria, mental confusion,15
cognitive disturbances,16 memory impairment,9 psychiatric
and motoric disturbances,6 in addition of other neuropsycho-
logical and neurological symptoms17 such as anxiety and irri-
tability.18,19 On the other hand and in addition to both the
activation of oxidative stress pathways and changing neuro-
transmitters levels in the brain,6,20 a recent study published
in 201121 pointed out that agonist binding and signal transduc-
tion are enhanced by Mn2+ through blocking guanosine nucle-
otide binding to G proteins in complex with 5-HT1A
receptors. This may clarify more the relationship between
manganism and the alterations it causes.
Mn2+ effects on 5-HT1A receptors in addition of Na+ ef-
fects, previously described, show that chemical ions may mod-
ify the GPCR properties and functions, thus may be used as
therapeutical adjutants (local usage) or as chemical additives
in experiments when preparing mediums (or media) for cell
cultures. More important such a ﬁnding will be helpful to de-
velop new conditions for in vitro studies and cell culture in neu-
ropharmacology and other aspects that are related to GPCRs
by taking into account the inﬂuence the surrounding area may
have on the pharmacological proﬁle and thus on the obtained
data and the ﬁnal interpretations of the experimental results.3. Cholesterol and membrane inﬂuence
The membrane molecular structures have been shown to have
an inﬂuence on GPCRs physiology. In addition to other sig-
naling molecules, trimeric G proteins and GPCR were sug-
gested to be entertained by cholesterol, saturated
phospholipids, glycolipids and sphingomyelin.22 Furthermore,
many papers have pointed to the important role cholesterol
and sphingolipid-enriched membrane domains play in GPCR
pathways’ signaling.23–32 Cholesterol of cell membranes is dis-
tributed in domains.33,34 In addition to the role of keeping
membranes structure,35 those domains were pointed out to
be involved in signals’ transduction.36
Indeed, several GPCRs functions have been pointed to as
modiﬁed by membrane cholesterol37,38 probably via interact-
ing directly with GPCR or/and by modulating the physical
properties of the plasma membrane (PM).39 A recent study40
brought out new elements about the possible link between
the GPCR signaling pathway and the inﬂuence of cell mem-
brane cholesterol content on GPCR mechanism, the results
supposed that cholesterol depletion affects the ability of d opi-
oid receptor (DOR) to transmit the signal rather than affecting
the receptor agonist binding site. The paper has highlighted
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ment and, thus deteriorates the coupling of DOR to covalently
bound Gi1a40 which disturbs signal transmission.
These ﬁndings point more to the need of further investiga-
tions about the role of GPCRs interaction with membrane lip-
ids, which will provide further data to improve the existent
therapeutics by taking into account the molecular interactions
of GPCRs within the plasma membrane.41 Thus, it will directly
have effect on the pharmacodynamic aspects of such novel
drugs.
4. Gap junction’s electrical synapses role in neuropathologies
Generally, the neuronal network has two fundamentally differ-
ent types of synapses. In addition to the chemical synapses, we
have Gap junctions (GJ) electrical synapses. GJ are intercellu-
lar channels which directly connect the cytoplasm of adjacent
cells; they are faster in information transfer compared to chem-
ical synapses.42 On the other hand, between neurons; GJ play a
role in the exchange of second messengers, including those
implicated in the GPCRs pathway like cAMP, IP3, Ca2+
and other small molecules.43
In neurosciences the connexin36 (Cx36) protein constitutes
an illustrative example, it is found in GJ of the hippocampus,
cerebral cortex, striatum, amygdala, the inferior olive, the cer-
ebellum and the olfactory bulb.44 Thus, it has a role in the
activities that are related to these brain structures. For that
matter, the passage of these second messengers through neuro-
nal GJ serves to coordinate activities between coupled neu-
rons. A recent study44 has pointed that Cx36 deﬁciency in
the mouse leads to behavioral changes in open ﬁeld activity,
anxiety-related behavior in the light–dark box and one-trial
object-place recognition. Thus, inﬂuence of the neural network
therefore; modiﬁes the cell response after the interaction of the
cerebral GPCRs with either endogenous ligands or exogenous
ligands (agonists, antagonists, inverse agonists. . .) according to
how Cx36 is or is not deﬁcient. Furthermore, the discoveries
suggest that the synchronization of neural network activity
in the hippocampus and neocortex via neuronal GJ plays a
role in the acquisition and/or consolidation of novel object
information.
By extrapolating, we can suppose that other neuronal junc-
tions may inﬂuence anxiety and other cerebral-related activi-
ties such as memory, locomotion and behavior-related
activities. Such activities are also mediated via GPCR systems,
thus the existence of junction plays an important role in both
physiology and pathology of pathways that have been linked
with GPCRs. On the other hand treatments targeting GPCR
or one of its pathway molecules may not be efﬁcient if the ori-
gin of pathogenesis is coming from the gap junctions rather
than from one of the GPCRs system molecules.
5. High and low-afﬁnity receptor states in vivo
A recent publication has pointed out the possible existence,
according to the afﬁnity state, of two populations of GPCRs
in vivo.45 It has suggested that for GPCRs two states may exist,
high afﬁnity state and low-afﬁnity state for agonist binding.
The method that could be used to evaluate and quantify it
may face a dynamic problem; In fact the kinetic nature of
pharmacodynamic phenomena can make the detection of thathigh and low afﬁnity agonist binding impossible.46–50 Methods
such as imaging with agonist radioligands and the use of genet-
ically modiﬁed mice may provide new tools to further study
this phenomenon.45
Understanding such differences and how the existence of
states of different afﬁnities can provide new elements in thera-
peutics that will be able to inﬂuence directly the afﬁnity of
GPCRs to their ligands, thus open more possibilities in both
drug development (improve drug properties) and drug research
(new targets) especially if it requires an unusual large con-
sumption of the drug or if the therapeutic window of the drug
is narrow. In fact some adjuvant may inﬂuence the afﬁnity and
thus modify the agonists’ pharmacodynamics. On the other
hand a possible genetic explanation of the high or the low
afﬁnities could indicate that gene therapy is also a potential
way to modify GPCR properties.45 However, if the therapeutic
index is acceptable, we can enhance the dose if either the afﬁn-
ity or the efﬁcacy is low rather than inﬂuencing the afﬁnity of
GPCRs to their ligands.6. Animal species inﬂuence on ligand–receptor interaction
One of the most important factors in both animal experiment
and cell culture researches are the choice of animal species and
the cell strain origin. A ligand may interact differently with the
same kind of receptor but coming from two different species.
Indeed, comparative studies between human H1R and guinea
pig H1R, have shown species-differences in afﬁnity, ligand
binding kinetics and rate constants for association and dissoci-
ation between human and guinea pig histamine H1-receptors
(hH1R and gpH1R) when interacting with histamine H1-
receptors (H1R) antagonist mepyramine and partial (H1R)
agonist phenoprodifen (a histaprodifen), and this because the
exchange of N-terminus and E2-loop inﬂuence on the afﬁnity
of phenoprodifen to H1R51; it inﬂuences also the binding
kinetics of the H1R antagonist mepyramine. Differences in
amino acid sequences of the transmembrane domains exist in
some positions within these domains of the H1R.52 The studies
were based on thermodynamic calculations, radioligand bind-
ing studies and the numerous new active- and inactive states
and GPCR crystal structures.52–54 Many biogenic amines such
as serotonin and dopamine have a chemical analogy and share
some physical and chemical properties with histamine, addi-
tionally they interact with the GPCR also, therefore, this result
may also be relevant for other biogenic amine receptors.
This ﬁnding highlights the importance of taking into ac-
count the differences that may exist between different species
regarding the ligand–receptor interactions, therefore suppose
that results which have been or that will be obtained in animal
experiments or cell cultures may not be valid for humans be-
cause of the interspecies possible differences. Importantly this
ﬁnding points more the importance of both species and cell
culture choices in researches, more importantly, in human clin-
ical trials in drug effect validations, interspecies differences
may also exist. The study of the role of serotonergic and sero-
tonergic pathways in decision making process55 supposed that
polymorphism in both of the dopamine transporter (DAT1)
and serotonin transporter (STin2) are implicated in individual
differences in striatal and amygdala responses during the deci-
sion making process which illustrates the inﬂuence genetic
polymorphism may have on GPCR related functions. In addi-
4 A. Ghanemi et al.tion, some serotonin receptors types are GPCRs which have
been linked to some neuropsychiatric functions56 supposing
the inﬂuence of the mentioned factors on different neuropsy-
chiatric disorders include the serotonergic pathway in the
process.
7. Conclusions and perspectives
Studying new elements about GPCR systems and pathways
will surely lead to ﬁnding out not only new therapies but also
explanations for numerous pathogenic phenomena, in addition
to the possibility of designing new research protocols and
eventually provide data to other research areas including
molecular biology and physiology.
The implications of GPCRs in vivo functions and processes
predict numerous side effects of drugs that interact
with GPCRs systems. Thus, GPCR-related system constitutes
a pharmacological target that needs particular pharma-
covigilance.Conﬂict of interest
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